SCHEMBL449461

SCHEMBL449461

C[C@@](Cc1ccc([N+](=O)[O-])cc1)(NC(=O)c1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.51
IKBKB O14920 1/20 0.50
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 3/20 0.47
POLB P06746 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GLA P06280 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
THRB P10828 1/20 0.47
MCL1 Q07820 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
NR1H4 Q96RI1 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
TP53 P04637 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL449460 1.00 DRD4 (0.51) DRD4IKBKBMEN1KMT2AMAPT
SCHEMBL5580414 0.80 CCR3 (0.48) MEN1KMT2AMAPT
SCHEMBL5580412 0.80 CCR3 (0.48) MEN1KMT2AMAPT
SCHEMBL22505235 0.77 HDAC3 (0.52) MEN1KMT2ANR1H4SMN1; SMN2NPC1
SCHEMBL6410116 0.75 SMN1; SMN2 (0.72) DRD4IKBKBMEN1KMT2AMAPT
SCHEMBL3936107 0.71 NPC1 (0.49) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL3936101 0.71 NPC1 (0.49) MEN1KMT2AMAPTPOLBKDM4E
SCHEMBL11327905 0.71 ALDH1A1 (0.42) MEN1KMT2AMAPTKDM4ETHRB
SCHEMBL1309030 0.71 GAA (0.48) MEN1KMT2AMAPTPOLBTHRB
SCHEMBL1309087 0.71 GAA (0.48) MEN1KMT2AMAPTPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592482-B2 CCR3 inhibition for ocular angiogenesis and macular degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2013-11-26 US claimed
US-20110268723-A1 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-11-03 US claimed
US-20090123375-A1 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2009-05-14 US claimed
WO-2007098113-A2 CCR3 INHIBITION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION UNIVERSITY OF KENTUCKY (US) 2007-08-30 WO claimed
US-20240191238-A1 BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-06-13 US disclosed
US-11912998-B2 Method of treating aging-associated cognitive impairment by reducing CCR3 THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2024-02-27 US disclosed
US-20220213487-A1 CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2022-07-07 US disclosed
US-11345756-B2 CCR3 inhibition for ocular angiogenesis and macular degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2022-05-31 US disclosed
US-11236340-B2 Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3) THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-02-01 US disclosed
US-20200399644-A1 CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2020-12-24 US disclosed
US-10626399-B2 Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-04-21 US disclosed
US-20200054745-A1 METHODS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION LASHKARI KAMERAN (US) 2020-02-20 US disclosed
US-20120064010-A1 CCR3 and its Ligands Are Therapeutic and Diagnostic Targets for Neovascular Age-Related Macular Degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2012-03-15 US disclosed
US-20110268723-A1 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-11-03 US disclosed
US-8008092-B2 CCR3 inhibition for ocular angiogenesis and macular degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2011-08-30 US disclosed
WO-2010138591-A1 CCR3 AND ITS LIGANDS ARE THERAPEUTIC AND DIAGNOSTIC TARGETS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2010-12-02 WO disclosed
WO-2010129351-A1 METHOD TO IDENTIFY AND TREAT AGE-RELATED MACULAR DEGENERATION SCHEPENS EYE RESEARCH INSTITUTE (US) 2010-11-11 WO disclosed
US-20090123375-A1 CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2009-05-14 US disclosed
WO-2007098113-A2 CCR3 INHIBITION FOR OCULAR ANGIOGENESIS AND MACULAR DEGENERATION UNIVERSITY OF KENTUCKY (US) 2007-08-30 WO disclosed
US-20070190055-A1 CCR3 inhibition for ocular angiogenesis and macular degeneration KENTUCKY RESEARCH FOUNDATION, UNIVERSITY OF 2007-08-16 US disclosed